Table 1.
Baseline characteristics of enrolled patients
| Variables | No. of patients (N=90) | % | |
|---|---|---|---|
| Age (years-old) | 61.4 (26.3-86.0) | 100 | |
| Male gender | 68 | 75.6 | |
| Etiology | |||
| HBV/HCV/NBNC | 59/17/14 | 65.6/18.9/15.6 | |
| Child-Pugh A/B | 76/14 | 84.4/15.6 | |
| ALBI grade I/II/III | 39/48/3 | 43.3/53.3/3.3 | |
| Portal vein thrombosis | |||
| 0/Vp1,2/Vp3,4 | 48/13/29 | 53.3/14.4/32.2 | |
| Extra-hepatic metastasis | 54 | 60.0 | |
| AFP (ng/ml) | 466.7 (2.0-1043407.0) | 100 | |
| <10/10-400/≥ 400 | 13/30/47 | 14.4/30.3/52.2 | |
| BCLC stage B/C | 16/74 | 17.8/82.2 | |
| Lines of systemic therapy | |||
| 1/2/>2 | 37/43/10 | 41.1/47.8/11.1 | |
| Prior locoregional therapy | 71 | 78.9 | |
| Resection/RFA or TACE | 27/44 | 38.0/62.0 | |
| Previous Sorafenib history | 47 | 52.2 | |
| Post PD therapy | 32 | 35.6 | |
| Sorafenib/Chemotherapy | 17 | 53.1 | |
| Regorafenib/Lenvatinib/Carbozantinib | 7 | 21.9 | |
| Atezolizumab plus Bevacizumab | 1 | 3.1 | |
| Others (RT/TACE/Resection) | 7 | 21.9 | |
| Overall IrAE | Any grade | Grade ≥ 3 | |
| Skin rash | 24 | 0 | 26.7/0 |
| Hepatitis | 23 | 7 | 25.6/7.8 |
| Colitis | 1 | 0 | 1.1/0 |
| Pneumonitis | 5 | 1 | 5.6/1.1 |
| Hypothyroidism | 6 | 0 | 6.7/0 |
| Adrenal insufficiency | 2 | 0 | 2.2/0 |
| Mortality | 40 | 44.4 | |
Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; IrAE, immune related adverse effect; NBNC, non hepatitis B and C virus; PD, progression disease; RFA, radiofrequency ablation; RT, radiotherapy; TACE, transarterial chemoembolization.